Stellenwert der PET-CT in der Beurteilung von Lymphomen: klinischer Aspekt

Zusammenfassung

Die PET-Untersuchung ist mittlerweile ein integraler Bestandteil der Diagnostik und Behandlung von Lymphompatienten geworden. V. a. bei Lymphomen mit hoher FDG-Avidität wie dem Hodgkin-Lymphom, dem diffus großzelligen B-Zell Lymphom oder dem follikulären Lymphom wird die PET-Untersuchung zur Therapiesteuerung und Optimierung eingesetzt. Dazu werden hier die wichtigste Indikation und Konsequenzen aus klinischer Sicht diskutiert.

Abstract

PET-CT is now an important part of diagnostics and treatment of lymphoma patients. Especially in lymphoma entities with a high FDG avidity such as Hodgkin lymphoma, diffuse large B-cell lymphoma or follicular lymphoma PET-scanning is used for optimization of treatment. Therefore, the most important indications and clinical consequences are discussed in this article.

Schlüsselwörter

FDG-Avidität - Therapiesteuerung - BEACOPPesc - Toxizität

Key words

FDG avidity - treatment optimization - BEACOPPesc - toxicity

• Literatur

• 1 Trotmann J, Barrington SF. The role of PET in first-line treatment of Hodgkin lymphoma. Lancet Hematology 2021; 8: e67-79
• 2 Radford J, Illidge T, Counsell C. et al. Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma. N Engl J Med 2015; 372: 1598-1607
• 3 Fuchs M, Goerge H, Kobe C. et al. Positron Emission Tomography–Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. Journal of Clinical Oncology 2019; 37: 2835-2845
• 4 Andre M, Girinsky T, Federico M. et al. Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. Journal of Clinical Oncology 2017; 35: 1786-1794
• 5 Borchmann P, Plütschow A, Kobe C. et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2021; 22: 223-234
• 6 Engert A, Haverkamp H, Kobe C. et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012; 379: 1791-1799
• 7 Borchmann P, Goerge H, Kobe C. et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2017; 390: 2790-2802
• 8 Casasnovas R, Bouabdallah R, Brice P. et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol 2019; 20: 202-215
• 9 Johnson P, Federico M, Kirkwood A. et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma. N Engl J Med 2016; 374: 2419-2429
• 10 Barrington SF, Trotmann J. The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma. Lancet Hematology 2021; 08: e80-93
• 11 Poeschel V, Held G, Ziepert M. et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet 2019; 394: 2271-2281
• 12 Persky DO, Li H, Stephens DM. et al. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol 2020; 38: 3003-3011
• 13 Bologna S, Vander Borght T, Briere J. et al. EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE-ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B-CELL LYMPHOMA (AAIPI=0): RESULTS OF THE PHASE 3 LYSA LNH 09-1B TRIAL. ICML 2021 oral presentation.
• 14 Jessica L, Brady JL, Michael S. et al. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood 2019; 133: 237-245